Atara Biotherapeutics net losses worse than expected by analysts

You are here: Home > Central Coast Health Watch > Current Article

Atara Biotherapeutics net losses worse than expected by analysts

By Staff Report / Wednesday, August 1st, 2018 / Comments Off on Atara Biotherapeutics net losses worse than expected by analysts

Second quarter net losses for Atara Biotherapeutics outpaced analyst expectations, nearly doubling from the same period in 2017 to $50.9 million. Research and development costs rose 82.5 percent to $33.4 million, including new clinical trials, increased headcount and its recent expansion into a new R&D headquarters in Thousand Oaks. The company received positive results from…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.